Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition

Journal of Immunology

Volumn 171, Issue 1, 2003, Pages 489-497

  Schiffer, Lena ^a   Sinha, Jayashree ^a   Wang, Xiaobo ^a   Huang, Weiqing ^a   Von Gonsdorff, Gero ^a   Schiffer, Mario ^a   Madaio, Michael P ^b   Davidson, Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE CXCL13; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; IMMUNE COMPLEX DEPOSITION; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE ACTIVATION;

EID: 0037868032     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.1.489     Document Type: Article

References (45)

1. Hahn, B. 1997. Animal models of systemic lupus erythematosus. In Dubois' Lupus Erythematosus. H. B. Wallace, ed. Williams & Wilkens, Baltimore, p. 339.
2. Wakeland, E. K., K. Liu, R. R. Graham, and T. W. Behrens. 2001. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397.
3. + T cells is required to suppress autoimmunity. J. Immunol. 149:3083.
4. Carreno, B. M., and M. Collins. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:29.
5. Grewal, I. S., and R. A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111.
6. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science 265:1225.
7. Mihara, M., I. Tan, Y. Chuzhin, B. Reddy, L. Budhai, A. Holzer, Y. Gu, and A. Davidson. 2000. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J. Clin. Invest. 106:91.
8. Mohan, C., Y. Shi, J. D. Laman, and S. K. Datta. 1995. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154:1470.
9. Daikh, D. I., B. K. Finck, P. S. Linsley, D. Hollenbaugh, and D. Wofsy. 1997. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 159:3104.
10. Wang, X., W. Huang, M. Mihara, J. Sinha, and A. Davidson. 2002. Mechanism of action of combined short term CTLA4Ig and anti-CD40L in murine SLE. J. Immunol. 168:2046.
11. Daikh, D. I., and D. Wofsy. 2001. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166:2913.
12. Balazs, M., F. Martin, T. Zhou, and J. Kearney. 2002. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17:341.
13. Russell, J. Q., T. Mooney, P. L. Cohen, B. MacPherson, R. J. Noelle, and R. C. Budd. 1998. Anti-CD40L accelerates renal disease and adenopathy in MRL-1pr mice in parallel with decreased thymocyte apoptosis. J. Immunol. 161:729.
14. Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639.
15. Luther, S. A., A. Bidgol, D. C. Hargreaves, A. Schmidt, Y. Xu, J. Paniyadi, M. Matloubian, and J. G. Cyster. 2002. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169:424.
16. + dendritic cells in murine lupus and preferential chemotaxis of b1 cells towards b1c. J. Exp. Med. 193:1393.
17. Takemura, S., A. Braun, C. Crowson, P. J. Kurtin, R. H. Cofield, W. M. O'Fallon, J. J. Goronzy, and C. M. Weyand. 2001. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167:1072.
18. Waer, M., B. Van Damme, P. Leenaerts, L. Roels, E. Van der Schueren, M. Vandeputte, and P. Michielsen. 1988. Treatment of murine lupus nephritis with cyclophosphamide or total lymphoid irradiation. Kidney Int. 34:678.
19. Cavallo, T., K. Graves, and N. A. Granholm. 1984. Murine lupus nephritis: effects of cyclophosphamide on circulating and tissue bound immunoreactants. Clin. Exp. Immunol. 55:67.
20. Austin, H. A., 3rd, A. D. Patel, C. A. Cadena, D. T. Boumpas, and J. E. Balow. 1997. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus. J. Rheumatol. 24:61.
21. Wang, X., W. Huang, L. E. Schiffer, M. Mihara, A. Akkerman, K. Hiromatsu, and A. Davidson. 2003. Effects of anti-CD154 treatment on B cells in murine SLE. Arthritis Rheum. 48:495.
22. Calame, K. L. 2001. Plasma cells: finding new light at the end of B cell development. Nat. Immunol. 2:1103.
23. Clynes, R., C. Dumitru, and J. V. Ravetch. 1998. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279:1052.
24. 1pr mice. J. Exp. Med. 190:1813.
25. Seery, J. P., V. Cattell, and F. M. Watt. 2001. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(beta-o-methyl)-fluoromethylketone. J. Immunol. 167:2452.
26. Dai, C., Z. Liu, H. Zhou, and L. Li. 2001. Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulointerstitial lesions in patients with lupus nephritis. Chin. Med. J. (Engl. Ed) 114:864.
27. Lema, G. P., H. Maier, E. Nieto, V. Vielhauer, B. Luckow, F. Mampaso, and D. Schlondorff. 2001. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J. Am. Soc. Nephrol. 12:1369.
28. Luther, S. A., T. Lopez, W. Bai, D. Hanahan, and J. G. Cyster. 2000. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12:471.
29. Amft, N., S. J. Curnow, D. Scheel-Toellner, A. Devadas, J. Oates, J. Crocker, J. Hamburger, J. Ainsworth, J. Mathews, M. Salmon, et al. 2001. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothetial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum. 44:2633.
30. Hjelmstrom, P., J. Fjell, T. Nakagawa, R. Sacca, C. A. Cuff, and N. H. Ruddle. 2000. Lymphoid tissue homing chemokines are expressed in chronic inflanunation. Am. J. Pathol. 156:1133.
31. Ngo, V. N., H. Korner, M. D. Gunn, K. N. Schmidt, D. S. Riminton, M. D. Cooper, J. L. Browning, J. D. Sedgwick, and J. G. Cyster. 1999. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189:403.
32. Wu, Q., B. Salomon, M. Chen, Y. Wang, L. M. Hoffman, J. A. Bluestone, and Y. X. Fu. 2001. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J. Exp. Med. 193:1327.
33. Aten, J., A. Roos, N. Claessen, E. J. Schilder-Tol, I. J. Ten Berge, and J. J. Weening. 2000. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J. Am. Soc. Nephrol. 11:1426.
34. Vissers. J. L., F. C. Hartgers, E. Lindhout, C. G. Figdor, and G. J. Adema. 2001. BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur. J. Immunol. 31:1544.
35. + dendritic cells (DC) in aged BWF1 mice which can be matured by TNF-alpha into BLC/CXCL13-producing DC. Eur. J. Immunol. 32:1881.
36. Lienenluke, B., T. Germann, R. A. Kroczek, and M. Hecker. 2000. CD154 stimulation of interleukin-12 synthesis in human endothelial cells. Eur. J. Immunol. 30:2864.
37. Thienel, U., J. Loike, and M. J. Yellin. 1999. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell. Immunol. 198:87.
38. Lutgens, E., L. Gorelik, M. J. Daemen, E. D. de Muinck, I. S. Grewal, V. E. Koteliansky, and R. A. Flavell. 1999. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5:1313.
39. Yellin, M. J., V. D'Agati, G. Parkinson, A. S. Han, A. Szema, D. Baum, D. Estes, M. Szabolcs, and L. Chess. 1997. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum. 40:124.
40. Herold, K. C., J. Lu, I. Rulifson, V. Vezys, D. Taub, M. J. Grusby, and J. A. Bluestone. 1997. Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J. Immunol. 159:4150.
41. Loetscher, P., M. Seitz, M. Baggiolini, and B. Moser. 1996. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184:569.
42. Venuprasad, K., P. Parab, D. V. Prasad, S. Sharma, P. R. Banerjee, M. Deshpande, D. K. Mitra, S. Pal, R. Bhadra, D. Mitra, et al. 2001. Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression. Eur. J. Immunol. 31:1536.
43. Abrams, J. R., M. G. Lebwohl, C. A. Guzzo, B. V. Jegasothy, M. T. Goldfarb, B. S. Goffe, A. Menter, N. J. Lowe, G. Krueger, M. J. Brown, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103:1243.
44. Huang, W., J. Sinha, J. Newman, B. Reddy, L. Budhai, R. Furie, A. Vaishnaw, and A. Davidson. 2002. The effect of anti-CD40 ligand antibody on B cells in human SLE. Arthritis Rheum. 46:1554.
45. Anolik, J., D. Campbell, C. Ritchlin, M. Holyst, S. Rosenfeld, C. Varnis, R. Felgar, M. Benyunes, R. Shields, L. Presta, et al. 2001. B lymphocyte depletion as a novel treatment for systemic lupus erythematosus (SLE): phase I/II trial of rituximab (rituxan) in SLE. Arthritis Rheum. 44:S387 (Abstr.).